3D molecular rendering of a mitochondrial membrane lipid bilayer, featuring cardiolipin molecules. At the center, a complex protein structure (representing Bcl-2) is dynamically binding to and enveloping several smaller protein units (representing Bax), physically preventing them from penetrating the membrane surface.
Image Credit: Scientific Frontline
Scientific Frontline: Extended "At a Glance" Summary: Bcl-2 Protein Mechanism in Cancer Resistance
The Core Concept: Bcl-2 is a cell-protective protein that prevents apoptosis (programmed cell death) by blocking death-inducing proteins, thereby allowing cancer cells to survive and proliferate even when exposed to lethal stress.
Key Distinction/Mechanism: During a normal apoptotic response, the protein Bax initiates cell death by forming pores in the mitochondrial membrane. Bcl-2 subverts this process by physically capturing and binding multiple Bax proteins simultaneously on the outer surface of the mitochondria. This multi-binding capability makes Bcl-2 highly efficient, meaning cancer cells only require a moderate increase in Bcl-2 production to successfully resist treatment.
Major Frameworks/Components:
- Apoptosis: The programmed cellular death sequence designed to eliminate old, damaged, or harmful cells, frequently triggered by chemotherapy and radiation therapy.
- Bax Protein: A pro-apoptotic, cell-killing protein that executes cell death by puncturing mitochondrial membranes.
- Bcl-2 Protein: An anti-apoptotic protein that neutralizes Bax, heavily implicated in tumor survival.
- Mitochondrial Membrane Dynamics: The biochemical battleground where Bax and Bcl-2 physically interact to determine cell survival.
- Cardiolipin: A specific mitochondrial lipid that typically facilitates Bax pore formation, though its effects can be overridden by elevated Bcl-2 levels.
Branch of Science: Molecular Biology, Oncology, Biochemistry, Biophysics.
Future Application: Detailed structural knowledge of the Bcl-2 and Bax interaction provides a precise pharmacological target. Future drug developments can focus on directly disabling the protective function of Bcl-2, effectively stripping tumors of their primary defense mechanism and re-sensitizing them to standard cancer therapies.
Why It Matters: Nearly half of all human cancers are associated with an overproduction of the Bcl-2 protein. Understanding the exact molecular mechanism by which it shields cancer cells from therapies addresses a major hurdle in modern oncology, offering a critical pathway to overcome treatment-resistant tumors and improve clinical outcomes.
Researchers at Umeå University have contributed new insights into how cancer cells protect themselves from cell death. The study provides a deeper understanding of how key proteins interact within the cell and could, in the long term, support the development of new cancer therapies.
The findings, published in the journal ACS Chemical Biology, show how a central protein can block apoptosis – the process that normally causes cancer cells to die.
Apoptosis is a form of programmed cell death that plays a crucial role during embryonic development, in removing old or damaged cells, and in enabling the immune system to function properly. When apoptosis does not work as it should, as in many cancers, cells can divide uncontrollably and form tumors.
Many cancer treatments, such as chemotherapy and radiotherapy, work by causing damage or stress in cells that triggers apoptosis. However, many tumors manage to evade this form of cell death as well, making them resistant to treatment.
Blocking death-inducing proteins
One of the most important proteins controlling apoptosis is the cell‑killing protein Bax. Once activated, Bax can initiate apoptosis by forming pores in the membranes of mitochondria. Another key protein from the same family, the cell‑protective protein Bcl‑2, instead prevents Bax from killing harmful cells. In nearly half of all human cancers, one of the underlying problems is an increased production of Bcl‑2, which promotes tumor growth and often leads to poor response to therapy.
“In our research, we have used advanced neutron experiments to show how Bcl‑2 protects cancer cells by blocking the death‑inducing proteins that are most often activated by therapy,” says Gerhard Gröbner, professor at Umeå University and lead author of the study.
The experiments show that Bcl‑2, which is located on the outer surface of the mitochondria, can capture and bind several Bax proteins at the same time. This makes the inhibition of cell death more efficient than previously thought. Cancer cells do not need to produce extremely large amounts of Bcl‑2 to protect themselves – even a moderate increase can be sufficient.
Opens up for new cancer treatments
The researchers also investigated how the composition of the mitochondrial membrane affects the interaction between the proteins. One particular lipid, cardiolipin, can promote apoptosis and help Bax form pores in the membrane. However, even in membranes containing cardiolipin, a sufficiently high level of Bcl‑2 can still prevent cell death.
“In the longer term, this type of knowledge could open up new opportunities for cancer treatment, for example by targeting Bcl‑2 and its protective function,” says Gerhard Gröbner.
Reference material: What Is: Mitochondrion
Additional information: The study was carried out in collaboration between researchers from Umeå University, Lund University, the European Spallation Source (ESS) in Lund, the ISIS Neutron and Muon Source and Diamond Light Source in the United Kingdom, and the Institut Laue‑Langevin (ILL) in France.
Published in journal: ACS Chemical Biology
Title: Avoiding Mitochondrial Apoptosis by the Bcl-2-Driven Bax Oligomerization on Membrane Surfaces
Authors: Sophie E. Ayscough, Luke A. Clifton, Jörgen Ådén, Sebastian Köhler, Nicolò Paracini, James Doutch, Éilís C. Bragginton, Anna E. Leung, Oliver Bogojevic, Jia-Fei Poon, Tamás Milán Nagy, Hanna P. Wacklin-Knecht, and Gerhard Gröbner
Source/Credit: Umeå University | Sara-Lena Brännström
Reference Number: mbio040726_01